Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration
- Authors
- Qureshi, Omer Salman; Kim, Hyung-Seo; Zeb, Alam; Choi, Jin-Seok; Kim, Hoo-Seong; Kwon, Jung-Eun; Kim, Myung-Sic; Kang, Jong-Ho; Ryou, Chongsuk; Park, Jeong-Sook; Kim, Jin-Ki
- Issue Date
- Jun-2017
- Publisher
- Taylor & Francis
- Keywords
- Lipid nanoparticles; docetaxel; sustained release; pharmacokinetics; bioavailability
- Citation
- Journal of Microencapsulation, v.34, no.3, pp.250 - 261
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Microencapsulation
- Volume
- 34
- Number
- 3
- Start Page
- 250
- End Page
- 261
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/12052
- DOI
- 10.1080/02652048.2017.1337247
- ISSN
- 0265-2048
- Abstract
- The aim of this study was to develop docetaxel-incorporated lipid nanoparticles (DTX-NPs) to improve the pharmacokinetic behaviour of docetaxel (DTX) after oral and parenteral administration via sustained release. DTX-NPs were prepared by nanotemplate engineering technique with palmityl alcohol as a solid lipid and Tween-40/Span-40/Myrj S40 as a surfactants mixture. Spherical DTX-NPs below 100 nm were successfully prepared with a narrow particle size distribution, 96% of incorporation efficiency and 686 times increase in DTX solubility. DTX-NPs showed a sustained release over 24 h in phosphate-buffered saline and simulated gastric and intestinal fluids, while DTX-micelles released DTX completely within 12 h. The half-maximal inhibitory concentration (IC50) of DTX-NPs against human breast cancer MCF-7 cells was 1.9 times lower than that of DTX-micelles and DTX solution. DTX-NPs demonstrated 3.7- and 2.8-fold increase in the area under the plasma concentration-time curve compared with DTX-micelles after oral and parenteral administration, respectively.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.